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Aerococci have certain cultivation characteristics. A well-known method of aerococcal cultivation uses indicator media 
which included the complex "oxolinic acid – etonium", but data indicating cases of conditionally pathogenic flora contamination 
due to the accumulation of microorganisms that are resistant to this complex have been obtained. Therefore, there was a need to 
search for new substances that would have a wide range of antagonistic activity in relation to the conditionally pathogenic flora 
and at the same time would not inhibit the growth of aerococci, and which would also be available and safe. The sensitivity of the 
A. viridans symbionts and conditionally pathogenic flora to the substances with antimicrobial activity of different groups was 
determined by the method of "wells". For research, A. viridans symbionts isolated from different microbiocenoses have been used. 
P. aeruginosa, S. aureus, K. pneumoniae, E. coli and C. albicans were used as conditionally pathogenic flora. Norfloxacin, 
pefloxacin, ofloxacin, gatifloxacin, levofloxacin, miramistin, decamethoxine, chlorhexidine, octenidine and boric acid were used 
as investigational drugs. Also, the optimal concentration of drugs which would suppress the growth of conditionally pathogenic 
flora, and would not show a negative effect on A. viridans was determined by serial dilutions. It was found that miramistin, 
norfloxacin and boric acid meet the necessary criteria. The serum dilutions method was used to determine the minimum inhibitory 
concentration (MIC) of these drugs in the experiment. Norfloxacin in a dosage of 12.5–50.0 μg/ml effectively inhibited the growth 
of the conditionally pathogenic flora, but also reduced the number of aerococci. The dose of 8.3 μg/ml met the criteria we needed, 
namely suppressing the growth of the conditionally pathogenic flora and not affecting aerococci. The concentration of miramistin 
and boric acid in a culture medium that showed a stong depressant effect on conditionally pathogenic flora and practically did not 
affect A. viridans was 50 μg/ml. In addition, miramistin and boric acid exhibited fungicidal action against C. albicans. 
Antimicrobial effects of the investigated drugs on the conditionally pathogenic flora was not complete in some cases, or inhibited 
the growth of aerococci at higher doses, so the effect of their rational combination on the conditionally pathogenic flora was 
investigated. As a result, an antimicrobial complex with optimal concentrations of substances (norfloxacin 8.3 μg/ml, myramistin 
50 μg/ml, boric acid 50 μg/ml), which effectively suppresses UPMF and does not affect the growth of symbionic A. viridans, was 
determined. The specified antimicrobial complex can be used for the production of modified media for isolation, cultivation and 
study of biochemical activity of A. viridans microorganisms. Properties of aerococci, grown on the nutrient medium with the 
studied drugs did not differ from aerococci, grown on nutrient media without additives.  
Keywords: aerococci; autosymbionts; cultivation of aerococci; indicator media; modified media.  
 
Іntroduction  
 
Aerococcus viridans is a bacterium that is present in the environ-
ment and was initially isolated from the air. Other types of Aerococcus 
have been obtained from different parts of the human body and animals 
(Collins et al., 1999; Nobukazu Saishu et al., 2009). Aerococci are com-
ponents of normal gut microbiota of animals (Wise & Siragusa, 2007; 
Senneby et al., 2016) and human intestinal flora. Along with this, there 
are cases of allocation of aerosols in humans and animals in various 
pathologies and these are associated, as a rule, with immuno-deficiency 
states. Initially, the Aerococcus genus, which included a single species – 
Aerococcus viridans was described. Subsequently, five new Aerococ-
cus species: Aerococcus urinae, A. sanguinicola, A. christensenii, A. 
urinaeequi and A. urinaehominis (Facklam&Elliot, 1995) have been 
identified. The clinical significance of these species was clearly 
established for A. urinae and A. viridans (Shelton-Dodge et al., 2011; 
Rasmussen et al., 2013; Humphries et al., 2014; Senneby et al., 2015).  
A. viridans are ubiquitous microorganisms, and have certain pecu-
liarities of cultivation (Williams & Hirch, 1953; Rizhenko et al., 2002; 
Facklam et al., 2003). Research carried out used displaying medias 
through which the allocation, identification and differentiation of 
aerococci were conducted (Good et al., 1966; Devrise et al., 1999; 
Kremenchuckij et al., 2003, 2009). The composition of the aforementio-
ned media for the selective allocation of various types of aerococci 
included the complex "oxolinic acid – etonium", which gave a selective 
effect of predominant aercocci growth in concentrations: oxalic acid – 
50 μg/ml, etonium – 5 μg/ml. In the process of use of these media, data 
indicating cases of conditionally pathogenic flora (CPF) contamination 
due to the accumulation of microorganisms that are resistant to the 
"oxolinic acid – etonium complex" were obtained. The above-mentio-
ned facts and increased incidence of infections caused by hospital strains 
with multi-resistance to chemotherapy (Uh et al., 2002; Yasukawa et al., 
2014; Gonzalez et al., 2017), especially methicillin-resistant Staphylo-
coccus aureus (MRSA) (Cho & Chung, 2017), have also created a need 
to search for new substances that would have a wide range of antagonis-
tic activity in turn on the CPF and inhibit the growth of aerococci at the 
same time and which should also be accessible and safe.  
The experimental method (Stepanskyi & Kremenchutskyi, 2014) made 
it possible to discover the sensitivity of the A. viridans symbionts to 
fluoroquinolones and determined that norfloxacin at a dosage of 
8.3 μg/ml practically did not affect the growth of aerococci and effecti-
vely suppresses the CPF. However, it was important to enhance the 
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selective effect of norfloxacin with other antimicrobial agents in order to 
receive stronger suppression of CPF. Therefore, the purpose of the 
study was to select a selective antibacterial complex that would suppress 
the growth of UPMF and would not affect the growth of A. viridans, 
with the possibility of using it for the production of modified media for 
isolation, cultivation and study of the biochemical activity of A. viridans 
microorganisms.  
 
Materials and methods  
 
The determination of the A. viridans symbionts and CPF sensitivity 
to the substances of different groups with antimicrobial activity was car-
ried out by the method of "wells" (Habriev, 2005; CLSI, 2010). As a 
dense nutrient medium, the Mühler-Hinton agar was used, in which the 
wells with a diameter of 8 mm were used, the "lawn" was sown with 
test strips and the test specimens (0.01 ml) were placed. The inoculation 
was incubated at 37 °C for 24 hours. The results of the experiment were 
recorded by measuring the diameter of the growth inhibition zone in mm.  
A. viridans symbionts isolated from different human and animal 
microbiocenoses were used for the study: A. viridans E34 (human intes-
tine), A. viridans O36 (human oral cavity ), A. viridans 5m2015 (mouse 
feces), A. viridans 3k2015 (rat feces), A. viridans 23 (human tonsils). As 
CPF, Pseudomonas aeruginosa АТСС 27853, Staphylococcus aureus 
209-р, Klebsiella pneumoniae ATCC 700603, Escherichia coli ATCC 
8739 and Candida albicans ATCC 885-653 were taken. Norfloxacin, 
pefloxacin, ofloxacin, gatifloxacin, levofloxacin, miramistin, decametho-
xine, chlorhexidine, octenidine, boric acid were used as investigational 
drugs. The number of studies was 5 for each microorganism.  
After determining the optimal, in terms of the purpose of the study, 
drugs, in order to minimize selective factors in nutrient media for gro-
wing aerococci, the optimal concentration of drugs was determined by 
the method of serial dilutions, which would suppress the growth of CPF, 
and would not show a negative effect on A. viridans. For inoculation, a 
standard microbial suspension equivalent to 0.5 on the Mc Farland stan-
dard diluted 100 times on a nutrient broth was used, after which the concen-
tration of the microorganism in it was approximately 106 CFU/ml. 
0.5 ml of inoculum was injected into each test tube containing 0.5 ml of 
the appropriate dilution of the test substance and into one test tube con-
taining 0.5 ml of the nutrient broth without the test drug ("negative" 
control). The final concentration of the microorganism in each test tube 
reached the requirements – approximately 5 · 105 CFU/ml. The test 
tubes were sealed with sterile cotton gauze plugs, test tube test tubes, 
except "negative" control for the test tube, incubated in a normal atmo-
sphere at 37 °C for 24 hours. The "negative" control tube was placed in 
a refrigerator at +4 °C, where the results were stored.  
To determine the presence of microorganism growth, tubes with 
inoculate were reviewed in transmitted light. In addition, further research 
on aerococci properties grown on media with the addition of study 
drugs and without them was conducted.  
Under the normal distribution law, the indicators are represented as 
an arithmetic average (M), a standard error of the average (m). Compa-
rison of statistical characteristics of different groups and dynamics ob-
servation was conducted using parametric and nonparametric criteria: 
assessment of the likelihood difference means for unrelated samples by 
Mann-Whitney (U), connected to multiple comparison – ANOVA with 
post-hoc analysis based on the Scheffe test and Dunnett test. The proba-
bility of differences in relative quantities is according to Fisher's exact 
two-tailed criterion (Fisher exact P, two-tailed). Statistically significant 
differences were considered when P< 0.05.  
 
Results  
 
Miramistin and boric acid were found to meet the necessary criteria 
in addition to norfloxacin in previous experiments. In the further experi-
ment, the minimum inhibitory concentrations (MICs) of drugs that 
suppressed the CPF growth and did not show a negative effect on 
A. viridans were determined by serial dilutions. Results of the norfloxa-
cin study are presented in Table 1. Norfloxacin in a dosage of 12.5–
50.0 μg/ml effectively inhibited the growth of the CPF, but also decrea-
sed the number of aerococci. The dose of 8.3 μg/ml met the criteria we 
needed, namely suppressing the growth of the CPF and not affecting 
aerococci. However, it was alarming that the dose of norfloxacin 6 μg/ml 
left a viable UPPF of 103–104 CFU/ml. To prevent the emergence of 
resistant to norfloxacin CPF strains when cultivating aerococci, as well 
as to enhance the action of the latter, attention was drawn to preparati-
ons of surface-active substances with bactericidal and fungicidal proper-
ties, safe and widely used in medical practice (miramistin and boric acid). 
In addition, no data were found on the resistance of microorganisms to 
these substances. It turned out that the sensitivity of the CPF to the 
aforementioned substances is different in the strength and spectrum of 
bactericidal action. The optimal concentrations of these substances that 
suppressed the growth of the CPF and did not affect the growth of 
aerococci were determined (Table 2, 3).  
Table 1  
Influence of norfloxacin on the opportunistic microflora  
and multibiotopic A. viridans co-cultivation (n = 5;  
number of microorganisms after 24 hours of cultivation, M ± m)  
Microorganisms 
(7 lg CFU/ml) 
Dosage of the preparation, μg/ml 
6.0 8.3 12.5 25.0 50.0 
Aerococcus viridans Е34 
(human intestine) 
6.60 ± 
0.16 
6.36 ± 
0.11 
6.18 ± 
0.12 
5.18 ± 
0.12** 
3.32 ± 
0.15** 
Aerococcus viridans О36 
(human oral cavity) 
6.56 ± 
0.16 
6.48 ± 
0.07 
5.37 ± 
0.10** 
3.10 ± 
0.10** 
2.96 ± 
0.13 
Aerococcus viridans 
5м2015 (mouse feces) 
6.30 ± 
0.09 
6.46 ± 
0.07 
5.31 ± 
0.09** 
5.16 ± 
0.10* 
3.40 ± 
0.11** 
Aerococcus viridans 
3к2015 (rat feces) 
6.62 ± 
0.04 
6.46 ± 
0.06 
5.04 ± 
0.13** 
3.45 ± 
0.12** 
3.20 ± 
0.14 
Aerococcus viridans 23 
(human tonsils) 
6.53 ± 
0.08 
6.42 ± 
0.12 
5.34 ± 
0.10** 
3.37 ± 
0.10** 
3.05 ± 
0.17 
Staphylococcus  
aureus 
3.31 ± 
0.09 --** -- -- -- 
Klebsiella  
pneumoniae 
4.62 ± 
0.11 --** -- -- -- 
Escherichia  
coli 
3.57 ± 
0.04 --** -- -- -- 
Pseudomonas  
aeruginosa 
4.71 ± 
0.11 --** -- -- -- 
Note: * – P < 0.05; ** – P < 0.001 compared to the previous dosage of the 
drug (Scheffe's criterion).  
As shown by the analysis of the data obtained (Table 2), the con-
centration of myramistin in the culture medium, which showed a strong 
depressant effect in relation to the conditionally pathogenic microflora 
and practically did not affect A. viridans, was 50 μg/ml. P. aeruginosa 
and K. pneumoniae were the most resistant to the investigated drug mic-
roorganisms in this concentration. Myramistin at concentration of 75 mg/ml 
effectively inhibited all pathogenic microflora, but at the same time 
reduced the aerococci concentration (103–104 CFU/ml). In addition, 
myramistin exhibited a fungicidal effect in relation to C. albicans.  
Similar results were obtained in the study of the effects of boric acid 
(Table 3). Boric acid concentration in the culture medium, which had a 
strong depressant effect on CPF and practically did not affect A. viridans 
was 50 μg/ml. P. aeruginosa and E. coli were the most resistant to the 
studied drug in this concentration microorganisms. Boric acid at a con-
centration of 75 μg/ml effectively suppressed all of the CPF, but at the 
same time lowered the concentration of aerococci (105 CFU/ml). In addi-
tion, miramistin and boric acid exhibited fungicidal action against C. al-
bicans. All studied aerococcus autosymbionts tolerated even the highest 
investigated concentrations of myramistin well without losing their 
properties (morphological, physiological, tinctorial, etc.).  
Despite the active antimicrobial effects of the investigated drugs on 
the CPF, this was not complete in some cases, or inhibited the growth of 
aerococci at higher doses, so the effect of their rational combination on 
the CPF was investigated. The results are presented in Table 4. The 
complex of all three drugs completely suppressed the CPF, which may 
be due to the summation of antimicrobial effects, with virtually no effect 
on the aerococci growth. Properties of aerococci grown on the nutrient 
medium with the studied drugs did not differ from aerococci grown on 
nutrient media without additives. That is why all these drugs were 
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combined into a single antimicrobial complex for the production of 
modified media for the isolation, cultivation and study of biochemical 
activity of A. viridans microorganisms.  
Table 2  
Effect of miramistin on the opportunistic microflora  
and multibiotopic A. viridans co-cultivation (n = 5; number  
of microorganisms after 24 hours of cultivation (Ig CFU/ml, M ± m)  
Microorganisms,  
7 lg CFU/ml 
Dosage of the preparation, μg/ml 
10 25 50 75 100 
Aerococcus viridans 
Е34 (human intestine) 
6.61 ± 
0.09 
6.54 ± 
0.07 
6.22 ± 
0.09 
4.40 ± 
0.13** 
3.42 ± 
0.19** 
Aerococcus viridans 
О36 (human oral cavity) 
6.48 ± 
0.14 
6.37 ± 
0.10 
5.31 ± 
0.15** 
3.17 ± 
0.12** 
2.77 ± 
0.10 
Aerococcus viridans 
5m2015 (mouse feces) 
6.57 ± 
0.08 
6.53 ± 
0.11 
5.31 ± 
0.13** 
3.43 ± 
0.06** 
3.08 ± 
0.15 
Aerococcus viridans 
3k2015 (rat feces) 
6.63 ± 
0.09 
6.61 ± 
0.12 
6.64 ± 
0.11 
4.57 ± 
0.08** 
3.40 ± 
0.06** 
Aerococcus viridans 23 
(human tonsils) 
6.80 ± 
0.09 
6.63 ± 
0.05 
5.48 ± 
0.08** 
3.30 ± 
0.14** 
3.47 ± 
0.13 
Staphylococcus aureus 3.31 ± 0.09 
0.86 ± 
0.13** --** -- -- 
Klebsiella pneumoniae 4.52 ± 0.09 
2.37 ± 
0.10** 
1.17 ± 
0.12** --** -- 
Escherichia coli 3.53 ± 0.11 --** -- -- -- 
Pseudomonas 
aeruginosa 
4.71 ± 
0.18 
2.31 ± 
0.15** 
1.02 ± 
0.08** --** -- 
Aerococcus viridans 
Е34 (human intestine) 
4.48 ± 
0.08 
2.16 ± 
0.10** --** -- -- 
Note: see Table 1.  
Discussion  
 
Selective antimicrobial additives are widely used to prepare nutrient 
media in microbiology for the cultivation of various microorganisms. 
Korean researchers Chon et al. (2014) have been successfully used poly-
myxin as a selective additive for the cultivation of Bacillus cereus. 
British scientists Hill et al. (2013) achieved good results in isolating 
C. difficile from environmental objects using cefoxitin-cycloserin-egg 
yolk agar with lysozyme.  
Table 3  
Effect of boric acid on the opportunistic microflora  
and multibiotopic A. viridans (n = 5; number of microorganisms 
after 24 hours of cultivation (Ig CFU/ml, M ± m)  
Microorganisms 
(7 lg CFU/ml) 
Dosage of the drug, μg/ml 
10 25 50 75 150 
Aerococcus viridans  
Е34 (human intestine) 
6.49 ± 
0.09 
6.38 ± 
0.12 
6.22 ± 
0.09 
5.08 ± 
0.10* 
3.32 ± 
0.15* 
Aerococcus viridans  
О36 (human oral cavity) 
6.61 ± 
0.06 
6.54 ± 
0.07 
6.38 ± 
0.12 
5.16 ± 
0.10* 
3.52 ± 
0.09* 
Aerococcus viridans 
5m2015 (mouse feces) 
6.59 ± 
0.15 
6.48 ± 
0.12 
6.40 ± 
0.13 
5.32 ± 
0.11* 
3.50 ± 
0.08* 
Aerococcus viridans 
3k2015 (rat feces) 
6.48 ± 
0.08 
6.46 ± 
0.07 
6.31 ± 
0.15 
5.19 ± 
0.12* 
3.43 ± 
0.13* 
Aerococcus viridans 23 
(human tonsils) 
6.61 ± 
0.06 
6.52 ± 
0.13 
6.42 ± 
0.12 
5.30 ± 
0.13* 
3.36 ± 
0.11* 
Staphylococcus aureus 3.31 ± 0.15 --* -- -- -- 
Klebsiella pneumoniae 4.43 ± 0.09 
2.49 ± 
0.05* --* -- -- 
Escherichia coli 4.48 ± 0.08 
2.47 ± 
0.15* 
1.08 ± 
0.10* --* -- 
Pseudomonas 
aeruginosa 
4.60 ± 
0.08 
2.40 ± 
0.11* 
1.12 ± 
0.07* --* -- 
Aerococcus viridans  
Е34 (human intestine) 
2.48 ± 
0.08 --* -- -- -- 
Note: see Table 1.  
In the absence of commercially available selective agents designed 
to isolate certain microorganisms, it is possible to use media with selec-
tive factors, including antibiotics. One study (Glass et al., 2009) evaluated 
the sensitivity and selectivity of four media for the isolation of Burk-
holderia mallei and B. pseudomallei (Ashdown agar – a special selective 
medium for isolation of B. pseudomallei, well described in the literature 
but not commercially available; three commercially available media: Burk-
holderia cepacia selective agar (BCSA), oxidation-fermentative-poly-
myxin B-bacitracin-lactose (OFPBL) agar and Pseudomonas cepacia 
(PC) agar for isolation of B. cepacia). The authors came to the conclu-
sion that Ashdown agar was the most sensitive medium for the isolation 
of B. pseudomallei, but it was unable to support the growth of B. mallei. 
The Czech authors Bunesova at al. (2015) successfully used environ-
ments supplemented by mupirocin to isolate and identify Bifidobacterium.  
Table 4  
Influence of norfloxacin, myramystine and boric acid on opportunistic microflora and A. viridans (n = 5, M  ±  m)  
Drug 
Aerococcus 
viridanssymbionts 
(7 lgCFU/ml) 
Staphylococcus 
aureus (7 lgCFU/ml) 
Klebsiella 
pneumoniae 
(7 lgCFU/ml) 
Escherichia coli 
(7 lgCFU/ml) 
Pseudomonas 
aeruginosa 
(7 lgCFU/ml) 
Candida albicans 
(7 lgCFU/ml) 
Norfloxacin, 8.3 μg/ml 6.43 ± 0.06 – –* –# –*# – 
Miramistin, 50 μg/ml 6.46 ± 0.07 – 1.17 ± 0.12 –# 1.02 ± 0.08 – 
Boric acid, 50 μg/ml 6.40 ± 0.06 – –* 1.08 ± 0.10 1.12 ± 0.07 – 
Norfloxacin + Miramistin + boric acid 6.41 ± 0.11 – –* –# –*# – 
Notes: * – P < 0.001 relative to the corresponding indicator when using miramistin at a dose of 50 μg/ml; # – P < 0.001 relative to the corresponding indicator 
for using boric acid at a dose of 50 μg/ml (Scheffer criterion).  
In another study (Vlková et al., 2015) a new selective medium with 
mupirocin, acetic acid and norfloxacin was proposed and evaluated. 
Among other things, the authors sought to identify an antibiotic that 
would suppress the growth of clostridia and allow the growth of bifido-
bacteria, as well as use of the identified substance to develop a selective 
culture for the cultivation of bifidobacteria. The susceptibility of bifido-
bacteria and clostridia to 12 antibiotics was tested on an agar by disk 
diffusion method. Only norfloxacin inhibited the growth of clostridia 
and did not affect the growth of bifidobacteria. Using both pure cultures 
and fecal specimens from infants, adults, calves, lambs and piglets, the 
optimal concentration of norfloxacin in hard growth media was deter-
mined as 0.2 mg/ml. The results showed that a hard medium containing 
norfloxacin (0.2 mg/ml) in combination with mupirocin (0.1 mg/ml) and 
acetic acid (0.001 ml/ml), is suitable for the isolation of bifidobacteria 
from fecal specimens of various origins. The authors recommend nor-
floxacin as a selective factor that inhibits the growth of fecal clostridia. 
Well-known selective media for the isolation of Fusobacterium spp. 
from clinical material include josamycin, vancomycin and norfloxacin 
(JVN) (3, 4, and 1 microgram per ml, respectively) as selective agents, 
plus 5% defibrinated horse blood. British researchers (Brazier et al., 1991) 
have successfully isolated the strains of F. naviforme, F. nucleatum and 
F. necrophorum from the respiratory membrane of healthy volunteers and 
F. varium and F. mortiferum strains from fecal suspensions contamina-
ted by these organisms using JVN medium.  
The experimental method (Stepanskyi & Kremenchutskyi, 2014) 
made it possible to discover the sensitivity of the A. viridans symbionts 
to fluoroquinolones and determined that norfloxacin at a dosage of 
8.3 μg/ml practically did not affect the growth of aerococci and effecti-
vely suppresses the CPF. However, it was important to enhance the 
selective effect of norfloxacin with other antimicrobial agents in order to 
receive stronger suppression of CPF. Therefore, the purpose of the 
study was to select a selective antibacterial complex that would suppress 
the growth of UPMF and would not affect the growth of A. viridans, 
with the possibility to use it for the production of modified media for 
isolation, cultivation and study of the biochemical activity of A. viridans 
microorganisms.  
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The complex of all three drugs completely suppressed the CPF, which 
may be due to the summation of antimicrobial effects, with virtually no 
effect on the aerococci growth. Properties of aerococci grown on the 
nutrient medium with the studied drugs did not differ from aerococci 
grown on nutrient media without additives. That is why all these drugs 
were combined into a single antimicrobial complex for the production 
of modified media for the isolation, cultivation and study of biochemi-
cal activity of A. viridans microorganisms.  
Due to the growing resistance to antibiotics, constant monitoring of 
the effectiveness of antimicrobial additives, especially antibiotics is clearly 
needed. The use of these additives as substances to which there are no 
cases of resistance has obvious advantages. Prior to the creation of an 
antimicrobial complex for the cultivation of A. viridans (norfloxacin 
8.3 μg/ml, miramistin 50 μg/ml, boric acid 50 μg/ml), we did not find 
cases of resistance to miramystin or boric acid, which is an unconditio-
nal advantage in combination with minimal resistance to norfloxacin and a 
positive experience with the use of this antibiotic as a selective supplement.  
 
Conclusions  
 
A complex of all three drugs (norfloxacin, miramistin, boric acid) 
completely suppresses the conditionally pathogenic microflora, which may 
be due to the summation of antimicrobial effects, with virtually no effect 
on the growth of aerococci. An antimicrobial complex with optimal 
concentrations of substances (norfloxacin 8.3 μg/ml, miramistin 50 μg/ml, 
boric acid 50 μg/ml) which effectively suppresses CPF and does not 
affect the symbiontic A. viridans growth was determined.  
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